The role of T-LAK cell-originated protein kinase in targeted cancer therapy

Mol Cell Biochem. 2022 Mar;477(3):759-769. doi: 10.1007/s11010-021-04329-5. Epub 2022 Jan 17.

Abstract

Targeted therapy has gradually become the first-line clinical tumor therapy due to its high specificity and low rate of side effects. TOPK (T-LAK cell-originated protein kinase), a MAP kinase, is highly expressed in various tumor tissues, while it is rarely expressed in normal tissues, with the exceptions of testicular germ cells and some fetal tissues. It can promote cancer cell proliferation and migration and is also related to drug resistance. Therefore, TOPK is considered a good therapeutic target. Moreover, a number of studies have shown that targeting TOPK can inhibit the proliferation of cancer cells and promote their apoptosis. Here, we discussed the biological functions of TOPK in cancer and summarized its tumor-related signaling network and known TOPK inhibitors. Finally, the role of TOPK in targeted cancer therapy was concluded, and future research directions for TOPK were assessed.

Keywords: Cancer resistance; Pathway; TOPK; Targeted therapy; Tumor metastasis.

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cell Proliferation / drug effects
  • Drug Delivery Systems*
  • Humans
  • Mitogen-Activated Protein Kinase Kinases* / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase Kinases* / metabolism
  • Neoplasm Proteins* / antagonists & inhibitors
  • Neoplasm Proteins* / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / enzymology
  • Protein Kinase Inhibitors / therapeutic use*
  • Signal Transduction / drug effects

Substances

  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • Mitogen-Activated Protein Kinase Kinases
  • PDZ-binding kinase